Liver Metastasis Clinical Trial
Official title:
A Phase II Study of Cryoablation Combined With Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis From Solid Tumors (CASTLE-04)
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib for patients with unresectable liver metastasis, who had progressed after, or were refractory to first- or later-line therapy.
Recent studies have suggested that local destruction of tumor tissue by cryoablation induced activation and maturation of dendritic cells and tumor-specific T cells by cross-presentation of tumor antigens. While pd-1 blocking antibody interferes with PD-1 mediated T-cell regulatory signaling. And combination of pd-1 blocking antibody plus lenvatinib showed increased ORR in many type of solid tumors. Therefore, the objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib in previously treated unresectable liver metastasis from solid tumors. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05524155 -
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
|
Phase 2 | |
Recruiting |
NCT02632201 -
Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT01715402 -
Optimization of Health Expenditure in Liver Surgery
|
N/A | |
Recruiting |
NCT01035385 -
Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)
|
Phase 3 | |
Withdrawn |
NCT02651090 -
Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced CT and/or MRI
|
Phase 3 | |
Withdrawn |
NCT01775280 -
Response of Hepatic Tumors to Radioembolization
|
Phase 2 | |
Completed |
NCT00068068 -
Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases
|
Phase 2 | |
Terminated |
NCT02453490 -
Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis
|
Phase 3 | |
Recruiting |
NCT04622423 -
Advanced Therapies for Liver Metastases
|
||
Completed |
NCT00892424 -
Sorafenib-RT Treatment for Liver Metastasis (SLIM)
|
Phase 1/Phase 2 | |
Completed |
NCT00028405 -
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
|
Phase 1 | |
Completed |
NCT03801915 -
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
|
Phase 2 | |
Completed |
NCT02218801 -
A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program
|
||
Completed |
NCT01834014 -
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
|
N/A | |
Completed |
NCT00083785 -
Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases
|
Phase 2 | |
Active, not recruiting |
NCT03428477 -
EPA for Metastasis Trial 2
|
Phase 3 | |
Completed |
NCT02316028 -
Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)
|
Phase 1/Phase 2 | |
Completed |
NCT01785212 -
The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver
|
N/A | |
Completed |
NCT03785210 -
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
|
Phase 2 | |
Recruiting |
NCT02042794 -
Pringle Manoeuvre Versus Portal Vein Clamping for Liver Resection
|
N/A |